BioAtla Investor Presentation Deck

CAB-AXL (BA3011) NSCLC AXL Expression in Relation to Anti-tumor Activity Considerable anti-tumor activity among patients regardless of AXL expression level bicatla % Change 40 30 20 10 -10 -20 -30 -40 -50 -60 I I 0 C C C 10 1 I I I 1 1 1 I 1 I I T 1 I Best %Change in Sum of Target Lesions BA3011 Q2W Mono 20 30 40 50 TmPS (%) 60 70 80 90 100 Anti-tumor activity seen among patients with AXL low expression level supports target agnostic development BioAtla| Overview 40

View entire presentation